Telix Pharmaceuticals Limited
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which … Read more
Market Cap & Net Worth: Telix Pharmaceuticals Limited (TLPPF)
Telix Pharmaceuticals Limited (PINK:TLPPF) has a market capitalization of $5.37 Billion ($5.37 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #4458 globally and #2792 in its home market, demonstrating a -15.62% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Telix Pharmaceuticals Limited's stock price $16.05 by its total outstanding shares 334724485 (334.72 Million).
Telix Pharmaceuticals Limited Market Cap History: 2019 to 2025
Telix Pharmaceuticals Limited's market capitalization history from 2019 to 2025. Data shows growth from $341.42 Million to $5.37 Billion (60.35% CAGR).
Telix Pharmaceuticals Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Telix Pharmaceuticals Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.62x
Telix Pharmaceuticals Limited's market cap is 6.62 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
103.93x
Telix Pharmaceuticals Limited's market cap is 103.93 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $341.42 Million | $3.48 Million | -$27.87 Million | 97.97x | N/A |
| 2020 | $1.00 Billion | $5.21 Million | -$44.89 Million | 192.63x | N/A |
| 2021 | $1.90 Billion | $7.60 Million | -$80.51 Million | 250.29x | N/A |
| 2022 | $1.58 Billion | $160.10 Million | -$104.08 Million | 9.87x | N/A |
| 2023 | $2.30 Billion | $502.55 Million | $5.21 Million | 4.58x | 441.61x |
| 2024 | $5.19 Billion | $783.21 Million | $49.92 Million | 6.62x | 103.93x |
Competitor Companies of TLPPF by Market Capitalization
Companies near Telix Pharmaceuticals Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Telix Pharmaceuticals Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Telix Pharmaceuticals Limited Historical Marketcap From 2019 to 2025
Between 2019 and today, Telix Pharmaceuticals Limited's market cap moved from $341.42 Million to $ 5.37 Billion, with a yearly change of 60.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $5.37 Billion | +3.55% |
| 2024 | $5.19 Billion | +125.45% |
| 2023 | $2.30 Billion | +45.66% |
| 2022 | $1.58 Billion | -16.90% |
| 2021 | $1.90 Billion | +89.33% |
| 2020 | $1.00 Billion | +194.12% |
| 2019 | $341.42 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Telix Pharmaceuticals Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.37 Billion USD |
| MoneyControl | $5.37 Billion USD |
| MarketWatch | $5.37 Billion USD |
| marketcap.company | $5.37 Billion USD |
| Reuters | $5.37 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.